デフォルト表紙
市場調査レポート
商品コード
1301159

バイオテクノロジーと製薬サービスアウトソーシング市場規模、シェア、動向分析レポート:サービス別、最終用途別、地域別、セグメント予測:2023年~2030年

Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Services (Consulting, Auditing & Assessment), By End-use (Pharma, Biotech), By Region, And Segment Forecasts, 2023 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 133 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
バイオテクノロジーと製薬サービスアウトソーシング市場規模、シェア、動向分析レポート:サービス別、最終用途別、地域別、セグメント予測:2023年~2030年
出版日: 2023年06月29日
発行: Grand View Research
ページ情報: 英文 133 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バイオテクノロジーと製薬サービスアウトソーシング市場の成長と動向

GrandView Research, Inc.の最新レポートによると、世界のバイオテクノロジーと製薬サービスアウトソーシング市場規模は2030年までに1,079億6,000万米ドルに達すると予測されています。

同市場は2023年から2030年にかけてCAGR 5.3%で成長すると予測されています。COVID-19のパンデミックは、バイオテクノロジーや製薬のサードパーティサービスプロバイダや臨床試験に大きな影響を与え、試験の遅延、中断、中止をもたらしました。パンデミックからの回復により、機械学習(ML)ベースのプラットフォーム、人工知能(AI)、医薬品製造の自動化、革新的な試験デザインの採用が増加し、今後数年間でCROとCMOの状況を一変させると予測されます。

競争力が高まる中、企業はリソースを最大限に活用し、イノベーションを促進するため、中核能力に集中しています。非中核機能をアウトソーシングすることで、新薬の開発・発見など主な能力に集中します。その結果、複数の製薬会社が新薬開発のために様々なアウトソーシング・サービス・プロバイダーと提携しています。例えば、2022年1月、モノクローナル抗体の開発企業であるHaemaLogiX社は、骨髄腫治療薬の候補であるKappaMabモノクローナル抗体を製造するためにLonza社とパートナーシップを締結しました。新規かつ革新的な治療法、例えば再生医療などに対するバイオ医薬品や製薬企業の投資は、医薬品開発サービスとともに研究開発活動を牽引しています。

低分子化合物とともに生物製剤の需要が高いことから、バイオテクノロジーや医薬品製造のための医薬品製造受託機関(CMO)や医薬品製造受託機関(CRO)のサービス・ポートフォリオが拡大しています。小規模な製薬/バイオテクノロジー企業は、自社で開発、製造、薬事、製品メンテナンス、製品設計、開発、製品試験、バリデーション、トレーニング、教育などを行う際に、実質的な専門知識や高価な能力の不足などの課題に直面しています。その結果、CMOやCROの成長に有利な機会が生まれています。受託サービスは成長し、戦略的で的を絞った計画的なものになりつつあります。

これらの要因は、市場全体におけるCMO/CROのシェアを高める上で極めて重要な役割を果たすと予想されます。価格競争の激化、規制上の課題、特許切れにより、バイオテクノロジーや製薬業界ではマージンが縮小しています。競合サービスは、これらの問題を克服するのに役立つため、企業の間では「戦略的競争力の武器」とみなされています。これらのサービスは、持続可能なサプライヤーを選択することで、長期的にはコスト削減につながるため、クライアントにコスト削減を提供します。また、生産・研究施設の運営・管理にかかる時間の節約にも役立ちます。研究開発と製造の請負は、低コストでの製品開発と製品の製造コストを可能にします。

さらに、アウトソーシングサービスは貿易障壁の克服を支援し、企業の海外市場への参入を容易にします。このような利点から、いくつかの企業は生産設備や熟練労働者の雇用に資本を投下するよりも、アウトソーシングサービスを選択します。さらに、同市場の主要企業数社は、同市場でサービスを拡大するため、提携、サービス開始、合併、買収など、さまざまな戦略的取り組みを実施しています。例えば、2022年4月、Covanceの親会社であるLabCorpは、細胞・遺伝子治療技術の開発企業であるXcell Biosciencesと提携し、細胞・遺伝子治療の研究能力を拡大しました。この契約により、LabcorpとXcellbioは細胞・遺伝子治療の有効性と安全性の向上を目的としたプロジェクトで協力することになります。

バイオテクノロジーと製薬サービスアウトソーシング市場レポートハイライト

  • 不正事例の増加、知的財産権の齟齬、技術革新の高まりにより、2022年にはコンサルティング分野が19.6%のシェアを占め、市場を独占する見込み
  • サービス別では、発展途上地域におけるジェネリック医薬品やバイオシミラー医薬品への注目の高まりにより、その他分野のCAGRが予測期間中5.3%と最も高くなると予想されます。
  • 製薬業界では、価格圧力が高まっていることやジェネリック医薬品の増加により、製薬会社が社内の業務を大規模にアウトソーシングしていることから、予測期間中のCAGRは5.5%になると予想されます。
  • 一方、バイオテクノロジー分野は市場で大きなシェアを占めています。これは、バイオテクノロジー製品のパイプラインが拡大しているためです。
  • 北米は市場を独占し、2022年には53.5%と最大の収益シェアを占めました。これは、多数のバイオテクノロジー企業や製薬企業が存在し、同地域のCROやCMOが提供するサービスの質が高いためです。
  • アジア太平洋地域では、規制の枠組みの改善、コスト削減の可能性の高さ、安価な熟練人材の存在により、予測期間中に最も高いCAGR 5.8%を記録すると予想されます。
  • 同市場の主要企業は、市場での存在感を高めるため、いくつかの戦略的な取り組みを行っています。例えば、2023年2月、高度ドラッグデリバリーソリューションを専門とするバイオテクノロジー企業Elektrofi社は、サーモフィッシャーサイエンティフィック社と製造委託契約を締結しました。この提携により、サーモフィッシャーサイエンティフィックの受託製造サービスの専門知識を活用し、エレクトロファイのドラッグデリバリー技術をサポートします。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
  • 調査手法
    • 情報調達
  • 情報またはデータ分析
  • 調査手法
  • 調査範囲と前提条件
  • 市場の形成と検証
  • 国別セグメントシェアの計算
  • データソースのリスト

第2章 エグゼクティブサマリー

  • 市場の見通し
  • セグメントの見通し
  • 地域の洞察
  • 競合考察
  • バイオテクノロジーと製薬サービスアウトソーシング市場のスナップショット
  • バイオテクノロジーと製薬サービスアウトソーシング市場セグメントのスナップショット
  • バイオテクノロジーと製薬サービスアウトソーシング市場の競合情勢のスナップショット

第3章 バイオテクノロジーと製薬サービスアウトソーシング市場の変数、動向、および範囲

  • 市場系統の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • バイオテクノロジーと製薬サービスアウトソーシング市場分析ツール
    • 業界分析- ポーターの分析
    • PESTEL分析
    • 最終用途の認識分析
    • サービス価格分析

第4章 バイオテクノロジーと製薬サービスアウトソーシング市場:サービスの推定・動向分析

  • セグメントダッシュボード
  • バイオテクノロジーと製薬サービスアウトソーシング市場:サービス変動分析、2022年および2030年
  • コンサルティング
    • コンサルティング市場収益推計と予測、2018~2030年
    • 規制コンプライアンス
    • 修復
    • 品質マネジメントシステムコンサルティング
    • その他
  • 監査と評価
    • 監査および評価市場収益推計および予測、2018~2030年
  • 薬事関連業務
    • 規制関連市場収益推計と予測、2018~2030年
    • 臨床試験の申請と製品登録
    • 修復
    • 規制に関する執筆と出版
    • その他
  • 製品のメンテナンス
  • 製品の設計と開発
  • 製品のテストと検証
  • トレーニングと教育
  • その他

第5章 バイオテクノロジーと製薬サービスアウトソーシング市場:エンドユースの推定・動向分析

  • セグメントダッシュボード
  • バイオテクノロジーと製薬サービスアウトソーシング市場:エンドユース変動分析、2022年および2030年
  • 製薬会社
  • バイオテクノロジー企業

第6章 バイオテクノロジーと製薬サービスアウトソーシング市場:地域推定・動向分析

  • バイオテクノロジーおよび製薬サービスアウトソーシング市場:地域変動分析、2022年および2030年
  • 北米
    • 規制の枠組み
    • 北米のバイオテクノロジーと製薬サービスアウトソーシング市場推計・予測、2018年から2030年
    • 米国
    • カナダ
  • 欧州
    • 規制の枠組み
    • 欧州のバイオテクノロジーと製薬サービスアウトソーシング市場推計・予測、2018年から2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 規制の枠組み
    • アジア太平洋地域のバイオテクノロジーと製薬サービスアウトソーシング市場推計・予測、2018年から2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • 規制の枠組み
    • ラテンアメリカのバイオテクノロジーと製薬サービスアウトソーシング市場推計・予測、2018年から2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東とアフリカ
    • 規制の枠組み
    • 中東およびアフリカのバイオテクノロジーと製薬サービスアウトソーシング市場推計・予測、2018年から2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 企業の分類
  • 企業の市場シェア分析、2022年
  • 戦略マッピング
  • 企業プロファイル・一覧表
    • The Quantic Group
    • IQVIA HOLDINGS, INC.
    • Parexel International Corporation
    • Lachman Consultant Services
    • GMP Pharmaceuticals
    • Concept Heidelberg GmbH
    • Covance, INC.
    • Charles River
    • PRA Health Sciences
    • ICON plc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By Services, 2018 - 2030 (USD Million)
  • Table 5 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By Services, 2018 - 2030 (USD Million)
  • Table 8 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 10 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 Canada Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 12 Canada Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 14 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 15 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 UK Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 17 UK Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 Germany Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 19 Germany Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 France Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 21 France Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 22 Italy Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 23 Italy Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Spain Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 25 Spain Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 27 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 28 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 29 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Norway Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 31 Norway Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Japan Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 36 Japan Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 China Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 38 China Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 India Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 40 India Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Australia Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 42 Australia Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 44 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 46 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 49 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 51 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 53 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 55 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 56 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 58 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 60 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 South Arabia Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 62 South Arabia Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 UAE Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 64 UAE Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Participant's overview
  • Table 68 Financial performance
  • Table 69 Key companies undergoing expansions
  • Table 70 Key companies undergoing acquisitions
  • Table 71 Key companies undergoing collaborations
  • Table 72 Key companies launching new products/services
  • Table 73 Key companies undergoing partnerships
  • Table 74 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation and validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Biotechnology and Pharmaceutical Services Outsourcing Market Outlook, 2018 - 2030 (USD Million)
  • Fig. 11 Biotechnology and Pharmaceutical Services Outsourcing Market Summary, 2021 (USD Million)
  • Fig. 12 Market trends & outlook
  • Fig. 13 Parent Market Outlook
  • Fig. 14 Ancillary Market Outlook
  • Fig. 15 Market driver analysis (Current & future impact)
  • Fig. 16 Market restraint analysis (Current & future impact)
  • Fig. 17 Company market position analysis
  • Fig. 18 Biotechnology and Pharmaceutical Services Outsourcing market, service outlook key takeaways (USD Million)
  • Fig. 19 Biotechnology and Pharmaceutical Services Outsourcing market: Service movement analysis (USD Million)
  • Fig. 20 Consulting market, 2018 - 2030 (USD Million)
  • Fig. 21 Regulatory compliance market, 2018 - 2030 (USD Million)
  • Fig. 22 Remediation market, 2018 - 2030 (USD Million)
  • Fig. 23 Quality management systems market, 2018 - 2030 (USD Million)
  • Fig. 24 Other consulting market, 2018 - 2030 (USD Million)
  • Fig. 25 Auditing and assessment market, 2018 - 2030 (USD Million)
  • Fig. 26 Regulatory affairs market, 2018 - 2030 (USD Million)
  • Fig. 27 Clinical trial applications & product registration market, 2018 - 2030 (USD Million)
  • Fig. 28 Regulatory writing & publishing market, 2018 - 2030 (USD Million)
  • Fig. 29 Legal representation market, 2018 - 2030 (USD Million)
  • Fig. 30 Other regulatory affairs market, 2018 - 2030 (USD Million)
  • Fig. 31 Product maintenance market, 2018 - 2030 (USD Million)
  • Fig. 32 Product design & development market, 2018 - 2030 (USD Million)
  • Fig. 33 Product testing & validation market, 2018 - 2030 (USD Million)
  • Fig. 34 Training & education market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 Biotechnology and pharmaceutical services outsourcing market: End Use movement analysis
  • Fig. 37 Biotechnology and pharmaceutical services outsourcing market End Use outlook: Key takeaways
  • Fig. 38 Pharma market, 2018 - 2030 (USD Million)
  • Fig. 39 Biotech market, 2018 - 2030 (USD Million)
  • Fig. 40 Regional outlook, 2018 & 2030
  • Fig. 41 Regional market dashboard
  • Fig. 42 Regional market place: Key takeaways
  • Fig. 43 North America biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 45 Canada biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 46 Europe biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 47 UK biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 48 Germany biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 49 France biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 57 China (Mainland) biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 58 India biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 60 Thailand biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 63 Brazil biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 65 Argentina biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 69 UAE biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 70 Kuwait biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-326-3

Biotechnology And Pharmaceutical Services Outsourcing Market Growth & Trends

The global biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 107.96 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 5.3% from 2023 to 2030. The COVID-19 pandemic has significantly impacted biotechnology and pharmaceutical third-party service providers as well as clinical trials, resulting in trial delays, suspensions, and terminations. The recovery from the pandemic has led to the increasing adoption of Machine Learning (ML)-based platforms, Artificial Intelligence (AI), automation in drug manufacturing, and innovative trial designs that are projected to transform the CRO and CMO landscape in the coming years.

With rising competitiveness, companies are concentrating on their core capabilities to maximize resources and foster innovation. Focus on their key competencies, such as the development and discovery of new medicines, by outsourcing non-core functions. As a result, several pharmaceutical companies collaborate with various outsourcing service providers for new drug development. For instance, in January 2022, HaemaLogiX, a developer of monoclonal antibodies entered into a partnership with Lonza to manufacture a myeloma drug candidate, KappaMab monoclonal antibody. Biopharmaceutical and pharmaceutical investments in novel and innovative therapies, for instance, regenerative medicine, are driving the R&D activity together with drug development services.

The high demand for biologics along with small molecules has led to the expansion of service portfolios of Contract Manufacturing Organizations (CMOs)/Contract Research Organizations (CROs) for biotechnology and pharmaceutical production. Small pharma/biotech companies are facing challenges while performing in-house development, manufacturing, regulatory affairs, product maintenance, product design, and development, product testing and validation, and training and education, such as a lack of substantial expertise and expensive capability. This, in turn, has created lucrative opportunities for the growth of CMOs and CROs. Contract services are growing and becoming strategic, targeted, and planned.

These factors are expected to play a pivotal role in enhancing the share of CMOs/CROs in the overall market. Growing pricing pressure, regulatory challenges, and patent expiration have led to shrinking margins in the biotech and pharmaceutical industry. Contract services are considered a "strategic competitive weapon" among companies, as these services help overcome these issues. These services offer cost savings to their clients as choosing sustainable suppliers could lead to reduced costs in the long run. They also help save time utilized in the operations and management of a production and research facility. Contract research and manufacturing allow low-cost product development and the manufacturing cost of a product.

Furthermore, outsourcing services assist in overcoming trade barriers and facilitate the entry of firms into the foreign market. Owing to these advantages, several firms choose to outsource services rather than invest capital in production equipment and hiring skilled labor. Furthermore, several key entities in the market are undertaking various strategic initiatives, such as partnerships, service launches, mergers, and acquisitions, to expand their services in the market. For instance, in April 2022, LabCorp, the parent company of Covance, collaborated with a developer of cell and gene therapy technologies, Xcell Biosciences, to expand its research capabilities in cell and gene therapies. Under this agreement, Labcorp and Xcellbio would collaborate on projects aimed at improving the efficacy & safety of cell and gene therapies.

Biotechnology And Pharmaceutical Services Outsourcing Market Report Highlights

  • The consulting segment is expected to dominate the market with a share of 19.6% in 2022 owing to a rise in the number of fraudulent cases, discrepancies in intellectual property rights, and a rise in technological innovations
  • Based on service, the others segment is expected to witness the highest CAGR of 5.3% over the forecast period owing to the increasing focus on generic and biosimilar in developing regions
  • The pharma segment is expected to witness a CAGR of 5.5% over the forecast period as the pharmaceutical companies outsource internal activities at a larger scale due to rising pricing pressure, and growth of generics in the industry
  • On the other hand, the biotechnology segment held a significant share of the market. This is due to the expanding biotech product pipelines
  • North America dominated the market and accounted for the largest revenue share of 53.5% in 2022 due to the presence of a large number of biotechnology and pharmaceutical companies and the quality of services offered by the CROs and CMOs in the region
  • In Asia Pacific, the market is anticipated to register the highest CAGR of 5.8% over the forecast period owing to improved regulatory frameworks, high scope for cost savings, and the presence of cheap skilled personnel
  • The key players in the market undertaking several strategic initiatives to strengthen their market presence. For instance, in February 2023, Elektrofi, a biotech company specializing in advanced drug delivery solutions, entered into a contract manufacturing agreement with Thermo Fisher Scientific. This collaboration will leverage Thermo Fisher Scientific's expertise in contract manufacturing services to support Elektrofi's drug delivery technology

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
    • 1.2.1. Information Procurement
  • 1.3. Information or Data Analysis
  • 1.4. Methodology
  • 1.5. Research Scope and Assumptions
  • 1.6. Market Formulation & Validation
      • 1.6.1.1. Country Market: CARG Calculation
  • 1.7. Country Based Segment Share Calculation
  • 1.8. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional Insights
  • 2.4. Competitive Insights
  • 2.5. Biotechnology and Pharmaceutical Services Outsourcing Market Snapshot
  • 2.6. Biotechnology and Pharmaceutical Services Outsourcing Market Segment Snapshot
  • 2.7. Biotechnology and Pharmaceutical Services Outsourcing Market Competitive Landscape Snapshot

Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing outsourcing of R&D activities
      • 3.2.1.2. Changing regulatory landscape
      • 3.2.1.3. Increasing focus on core competencies by pharmaceutical and biotechnology companies
      • 3.2.1.4. Growing drug development costs coupled with high clinical development failure rates
      • 3.2.1.5. Increasing mergers and collaborations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Monitoring issues and lack of standardization
      • 3.2.2.2. Loss of control
      • 3.2.2.3. Data security issues
  • 3.3. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
    • 3.3.3. End-use Perception Analysis
      • 3.3.3.1. Why do you outsource Biotechnology and Pharmaceutical services to CROs?
      • 3.3.3.2. Percentage of outsourcing of different services.
      • 3.3.3.3. Importance of CRO selection parameters (Ranking from 1 to 5, where 1 - least important and 5 - most important).
    • 3.3.4. Service Price Analysis
      • 3.3.4.1. Pricing strategy
      • 3.3.4.1.1. Transactional business models
      • 3.3.4.1.2. Performance-based business models
      • 3.3.4.1.3. Outcome-based business models
      • 3.3.4.2. Consulting rates
      • 3.3.4.3. Heat map for pricing analysis

Chapter 4. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis, USD Million, 2022 & 2030
  • 4.3. Consulting
    • 4.3.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Regulatory Compliance
      • 4.3.2.1. Regulatory Compliance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Remediation
      • 4.3.3.1. Remediation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Quality Management Systems Consulting
      • 4.3.4.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Auditing and Assessment
    • 4.4.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Regulatory affairs
    • 4.5.1. Regulatory affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Clinical Trial Applications & Product Registration
      • 4.5.2.1. Clinical Trial Applications & Product Registration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Remediation
      • 4.5.3.1. Remediation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Regulatory Writing & Publishing
      • 4.5.4.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Product Maintenance
    • 4.6.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Product Design & Development
    • 4.7.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Product Testing & Validation
    • 4.8.1. Product Testing & Validation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Training & Education
    • 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis, USD Million, 2022 & 2030
  • 5.3. Pharmaceutical Companies
    • 5.3.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Biotech Companies
    • 5.4.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Estimates & Trend Analysis

  • 6.1. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis, 2022 & 2030
  • 6.2. North America
    • 6.2.1. Regulatory Framework
    • 6.2.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Competitive Scenario
      • 6.2.4.3. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Regulatory Framework
    • 6.3.2. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Prevalence Insights
      • 6.3.5.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Prevalence Insights
      • 6.3.6.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Prevalence Insights
      • 6.3.7.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Prevalence Insights
      • 6.3.8.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Prevalence Insights
      • 6.3.9.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Competitive Scenario
      • 6.3.10.3. Prevalence Insights
      • 6.3.10.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Regulatory Framework
    • 6.4.2. Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Prevalence Insights
      • 6.4.3.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Prevalence Insights
      • 6.4.4.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Prevalence Insights
      • 6.4.5.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Prevalence Insights
      • 6.4.6.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Prevalence Insights
      • 6.4.7.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.8. South Korea
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Competitive Scenario
      • 6.4.8.3. Prevalence Insights
      • 6.4.8.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Regulatory Framework
    • 6.5.2. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East & Africa
    • 6.6.1. Regulatory Framework
    • 6.6.2. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Share Analysis, 2022
  • 7.3. Strategy Mapping
  • 7.4. Company Profiles/Listing
    • 7.4.1. The Quantic Group
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. IQVIA HOLDINGS, INC.
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Parexel International Corporation
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Lachman Consultant Services
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. GMP Pharmaceuticals
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Concept Heidelberg GmbH
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Covance, INC.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Charles River
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. PRA Health Sciences
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. ICON plc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives